These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 9164187

  • 1. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia.
    Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M.
    J Clin Oncol; 1997 May; 15(5):1796-802. PubMed ID: 9164187
    [Abstract] [Full Text] [Related]

  • 2. Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.
    Visani G, Milligan D, Leoni F, Chang J, Kelsey S, Marcus R, Powles R, Schey S, Covelli A, Isidori A, Litchman M, Piccaluga PP, Mayer H, Malagola M, Pfister C.
    Leukemia; 2001 May; 15(5):764-71. PubMed ID: 11368437
    [Abstract] [Full Text] [Related]

  • 3. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
    Advani R, Saba HI, Tallman MS, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Sikic BI, Greenberg PL.
    Blood; 1999 Feb 01; 93(3):787-95. PubMed ID: 9920827
    [Abstract] [Full Text] [Related]

  • 4. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
    Dahl GV, Lacayo NJ, Brophy N, Dunussi-Joannopoulos K, Weinstein HJ, Chang M, Sikic BI, Arceci RJ.
    J Clin Oncol; 2000 May 01; 18(9):1867-75. PubMed ID: 10784627
    [Abstract] [Full Text] [Related]

  • 5. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC).
    Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E, Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P.
    Adv Exp Med Biol; 1999 May 01; 457():47-56. PubMed ID: 10500779
    [Abstract] [Full Text] [Related]

  • 6. Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
    O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV.
    Pediatr Blood Cancer; 2010 May 01; 54(5):694-702. PubMed ID: 20209646
    [Abstract] [Full Text] [Related]

  • 7. Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia.
    Thomas X, Cambier N, Taksin AL, Reman O, Vekhoff A, Pautas C, Leblond V, Soler-Michel P, Ecstein-Fraïssé E, Archimbaud E.
    Leuk Res; 2000 Nov 01; 24(11):957-63. PubMed ID: 11086179
    [Abstract] [Full Text] [Related]

  • 8. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen.
    Ho AD, Lipp T, Ehninger G, Illiger HJ, Meyer P, Freund M, Hunstein W.
    J Clin Oncol; 1988 Feb 01; 6(2):213-7. PubMed ID: 3422260
    [Abstract] [Full Text] [Related]

  • 9. Mitoxantrone and constant infusion etoposide for relapsed and refractory acute myelocytic leukemia.
    Paciucci PA, Davis RB, Holland JF, Martelo O, Schiffer CA.
    Am J Clin Oncol; 1990 Dec 01; 13(6):516-9. PubMed ID: 2239806
    [Abstract] [Full Text] [Related]

  • 10. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R, Guardia R, Altés A, Sureda A, Brunet S, Sierra J.
    Haematologica; 1999 Mar 01; 84(3):226-30. PubMed ID: 10189387
    [Abstract] [Full Text] [Related]

  • 11. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.
    O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M.
    Cancer; 1991 Aug 15; 68(4):691-4. PubMed ID: 1855168
    [Abstract] [Full Text] [Related]

  • 12. A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.
    Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR.
    Leuk Res; 2000 Jul 15; 24(7):567-74. PubMed ID: 10867130
    [Abstract] [Full Text] [Related]

  • 13. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420.
    Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA.
    J Clin Oncol; 1999 Sep 15; 17(9):2831-9. PubMed ID: 10561359
    [Abstract] [Full Text] [Related]

  • 14. Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.
    Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G.
    J Clin Oncol; 1994 Jan 15; 12(1):141-8. PubMed ID: 8270970
    [Abstract] [Full Text] [Related]

  • 15. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D.
    Blood; 1991 May 01; 77(9):1894-900. PubMed ID: 2018832
    [Abstract] [Full Text] [Related]

  • 16. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.
    Tallman MS, Lee S, Sikic BI, Paietta E, Wiernik PH, Bennett JM, Rowe JM.
    Cancer; 1999 Jan 15; 85(2):358-67. PubMed ID: 10023703
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemia.
    Lazzarino M, Morra E, Alessandrino EP, Orlandi E, Pagnucco G, Merante S, Bernasconi P, Inverardi D, Bonfichi M, Bernasconi C.
    Eur J Haematol; 1989 Nov 15; 43(5):411-6. PubMed ID: 2612614
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.
    Bauer KS, Karp JE, Garimella TS, Wu S, Tan M, Ross DD.
    Leuk Res; 2005 Mar 15; 29(3):263-71. PubMed ID: 15661261
    [Abstract] [Full Text] [Related]

  • 19. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
    Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E.
    Leukemia; 1996 Oct 15; 10(10):1563-9. PubMed ID: 8847890
    [Abstract] [Full Text] [Related]

  • 20. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).
    Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, Rowe JM.
    J Clin Oncol; 2004 Mar 15; 22(6):1078-86. PubMed ID: 15020609
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.